Statement by PMPRB Chairperson on changes to the Patented Medicines Regulations
Ottawa, ON — Patented Medicine Prices Review Board
Patented Medicine Prices Review Board (PMPRB) Chairperson Dr. Mitchell Levine made the following statement regarding Health Canada’s final amendments to the Patented Medicines Regulations, which were announced today:
“With these amendments, the PMPRB now has the tools and information needed to meaningfully protect Canadian consumers from excessive prices today and into the future. We would like to thank the Minister of Health for placing her confidence in our ability to deliver on the Government’s commitment to make prescription drugs more affordable and accessible for all Canadians.”
The PMPRB intends to consult on new draft Guidelines this fall once its Board has had an opportunity to examine the final version of the regulatory amendments. The draft Guidelines will be subject to a robust consultation process with stakeholders and interested members of the public, the details of which will be made available in the coming months. The PMPRB will ensure that the consultation schedule gives stakeholders ample time to prepare for the coming into force of the regulatory amendments on July 1, 2020.
The PMPRB looks forward to open and constructive dialogue with our partners and stakeholders in the coming months as it works to make the necessary changes to its Guidelines to give effect to the regulatory amendments.
PMPRB Media Relations
TTY (telecommunications device for the hearing impaired) – 613-288-9654
Follow us on Twitter: @PMPRB_CEPMB
Report a problem or mistake on this page
- Date modified: